Analysts and Calls -- UBS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls -- UBS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (5)	12/6/2002 6:31:04 PM
From: Icebrg	Read Replies (1) of 19

I wonder if Gitkin was using the Risk Brothers as undercover agents? Or if he was out to prove that there is a Chinese Wall of sorts after all. At least at UBS's place. Or if he just has lost his general sense of direction. I suppose he will come out of this looking very smart. Or a complete idiot. The crowds seems still to like to follow their leaders. The turnover was 12 times the normal today. With a drop of 18 % in the market cap. On October 22 he was btw. of the opinion that the company's share price should be trending towards 18 USD. Which he one month later slashed to 4-6 USD. Bad day at the job, or what? At least one of them. stockselector.com (Interesting site btw.). A year ago he was very much in favour of the deal. Andrew Gitkin, an analyst at UBS Warburg, said the deal would be worth up to $500m. "The magnitude of this deal represents a strong validation of [Isis's] drug discovery platform, and the company's ability to consistently attract major pharmaceutical/biotech collaborative partners," he said. home.wanadoo.nl And some background info on Gitkin. He has been around for some time and should really had known better. Mr. Gitkin is an executive director in the healthcare group of UBS Warburg Equity Research. An analyst since 1994, he specializes in coverage of the biotechnology sector. In 1997 and 1998, Mr. Gitkin was one of the top three rated long-term care analysts according to the Greenwich Associates poll of research analysts. Prior to joining UBS Warburg, Mr. Gitkin was the healthcare service providers industry analyst at PaineWebber Incorporated. Before that Mr. Gitkin held various senior research positions at Salomon Smith Barney and most recently was a senior analyst and head of the health care group, where he specialized in senior long-term care (skilled nursing and assisted living). Mr. Gitkin received his B.B.A from Emory University, where he graduated with distinction. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next